Navigation Links
Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Date:11/5/2008

TUSTIN, Calif., Nov. 5 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that senior management will present at the Rodman & Renshaw 10th Annual Healthcare Conference on Tuesday, November 11, 2008 at 2:00 pm ET. The conference will be held at the New York Palace Hotel in New York City.

For more information about this conference, please visit: http://www.rodmanandrenshaw.com/conferences?id=19

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and serious virus infections. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Contacts:

GendeLLindheim BioCom Partners

Investors Media

info@peregrineinc.com Barbara Lindheim

(800) 987-8256 (212) 918-4650


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)...  Sangamo BioSciences, Inc. (NASDAQ: SGMO ) ... accomplishments. For the second quarter ended ... of $7.0 million, or $0.10 per share, compared to ... share, for the same period in 2013. As of ... marketable securities and interest receivable of $236.7 million. ...
(Date:7/23/2014)... ANGELES , July 23, 2014 /PRNewswire-iReach/ -- Think ... cognitive performance for the long term. They are the ... edge of sustained energy as an alternative to the ... Think Drinks on Indiegogo on July 29, 2014, with ... 30-day campaign. Photo - http://photos.prnewswire.com/prnh/20140723/129697 ...
(Date:7/23/2014)...  Having the right people at the table for ... growth and achieving clinical and operational goals. The 22 ... July 20-22, 2014, in San Diego ... healthcare experts discussing how partnerships have positively impacted their ... Chief Executive Officer of Cape Regional Medical Center located ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 DuPont Pioneer ... business as vice president of Agricultural Biotechnology (ABT), effective ... where he served most recently as president, chief executive ... and business leadership in the seed and crop protection ... Paul E. Schickler , president of DuPont Pioneer. ...
Breaking Biology Technology:Sangamo BioSciences Reports Second Quarter 2014 Financial Results 2Sangamo BioSciences Reports Second Quarter 2014 Financial Results 3Sangamo BioSciences Reports Second Quarter 2014 Financial Results 4Sangamo BioSciences Reports Second Quarter 2014 Financial Results 5Sangamo BioSciences Reports Second Quarter 2014 Financial Results 6Sangamo BioSciences Reports Second Quarter 2014 Financial Results 7Sangamo BioSciences Reports Second Quarter 2014 Financial Results 8Sangamo BioSciences Reports Second Quarter 2014 Financial Results 9truBrain Neuroscientists To Launch More Effective, Healthier Alternative To Energy Drinks On Indiegogo 2MSC and Cape Regional Medical Center Partner to Improve Cost, Quality and Outcomes 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3
... Testing Management " Conference, Sept 23-25, that the American Filtration ... be seven short courses on September 22, 2008. Two of ... , ... Richfield, MN (PRWEB) August 8, ...
... ISELIN, N.J., Aug. 7 Pharmos Corporation,(Nasdaq: PARS ) ... The Company recorded a net loss of $2.7 million, or ... net loss of $4.6 million, or,$0.18 per share, in the ... June 30, 2008., The decrease in net loss for ...
... SOUTH SAN FRANCISCO, Calif., Aug. 7 Anesiva,Inc. (Nasdaq: ... the second quarter and six months ended June 30, ... advance for Anesiva as we,introduced Zingo(TM) in the U.S. ... executive officer. "In addition, I,m pleased,to report that our ...
Cached Biology Technology:Microfiltration Membrane and Ultrafiltration Membrane Training 2Microfiltration Membrane and Ultrafiltration Membrane Training 3Pharmos Corporation Reports 2008 Second Quarter Results 2Pharmos Corporation Reports 2008 Second Quarter Results 3Pharmos Corporation Reports 2008 Second Quarter Results 4Pharmos Corporation Reports 2008 Second Quarter Results 5Anesiva Announces Second Quarter 2008 Financial Results and Update 2Anesiva Announces Second Quarter 2008 Financial Results and Update 3Anesiva Announces Second Quarter 2008 Financial Results and Update 4Anesiva Announces Second Quarter 2008 Financial Results and Update 5Anesiva Announces Second Quarter 2008 Financial Results and Update 6Anesiva Announces Second Quarter 2008 Financial Results and Update 7Anesiva Announces Second Quarter 2008 Financial Results and Update 8
(Date:7/23/2014)... 2014 BCC Research ... GLOBAL MARKETS AND TECHNOLOGIES FOR SENSORS , the global ... grow to nearly $154.4 billion by 2020, with a ... image, flow, and level sensors segment is moving at ... http://photos.prnewswire.com/prnh/20140723/694805 ) , Sensors have become indispensable ...
(Date:7/23/2014)... Streptococcus mutans , one of the principal bacteria ... in its genetic material over time, possibly coinciding ... humanity. This is highlighted in a study ... (UAB) and the Laboratorio Nacional de Genmica para ... in Mexico who, for the first time, have ...
(Date:7/23/2014)... no cure exists for Alzheimer,s disease, the devastating ... But scientists are now reporting new progress on ... treatment, that shows promise as a potential oral ... Journal of Medicinal Chemistry . , Carlo ... in a healthy brain, the protein known as ...
Breaking Biology News(10 mins):Global Market for Sensors to Reach Nearly $154.4 Billion in 2020; Image Sensors Moving at 11.7% 2Global Market for Sensors to Reach Nearly $154.4 Billion in 2020; Image Sensors Moving at 11.7% 3Ancient genetic material from caries bacterium obtained for the first time 2
... Antarctic ice shelves to shrink and split apart, yielding thousands ... a new study in this week’s journal Science these floating ... miles across – are having a major impact on the ... ocean life, with thriving communities of seabirds above and a ...
... biofactories for the production of various beneficial human drugs, ... into mushrooms. , "There has always been a recognized ... for the mass production of commercially valuable proteins," said ... Chair in spawn science and professor of plant pathology ...
... Research Hospital have discovered how a single molecular “on switch” ... and memory capabilities to glucose production in the liver. ... transcription factor—a molecule that binds to a section of DNA ... specific protein for which it codes. CREB activates genes in ...
Cached Biology News:Antarctic icebergs -- Hotspots of ocean life 2Antarctic icebergs -- Hotspots of ocean life 3Modified mushrooms may yield human drugs 2St. Jude study shows genes play an unexpected role in their own activation 2
Anti-20S proteasome subunits alpha 1, 2, 3, 5, 6 & 7, clone MCP231 Immunogen: Dinitrophenylated proteasomes Molecular Weight: 29 and 32 kDa....
Anti-ADP-Ribosylation Factor 1, clone 3F1 Immunogen: Synthetic peptide corresponding to the C-terminal amino acid sequence of human ARF1. Available Date: 38495...
Myeloid Marker (BM-1)...
Request Info...
Biology Products: